Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Abiraterone Acetate
/ therapeutic use
Androgen Antagonists
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Antineoplastic Agents, Hormonal
/ therapeutic use
Benzamides
Biopsy, Large-Core Needle
Bone Neoplasms
/ secondary
Docetaxel
/ therapeutic use
Endosonography
Health Resources
Health Services Accessibility
Humans
Iraq
Kallikreins
/ metabolism
Kuwait
Lebanon
Lymph Node Excision
Magnetic Resonance Imaging
Male
Margins of Excision
Middle East
Neoplasm Metastasis
Nitriles
Phenylthiohydantoin
/ analogs & derivatives
Positron-Emission Tomography
Prostate-Specific Antigen
/ metabolism
Prostatectomy
Prostatic Neoplasms
/ diagnosis
Prostatic Neoplasms, Castration-Resistant
/ diagnosis
Radiotherapy, Adjuvant
Risk
Salvage Therapy
Saudi Arabia
Syria
Consensus
Middle East
Multidisciplinary
Prostate cancer
Resource-stratified recommendations
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
21
05
2019
accepted:
04
07
2019
pubmed:
13
7
2019
medline:
29
12
2020
entrez:
13
7
2019
Statut:
ppublish
Résumé
Prostate cancer care in the Middle East is highly variable and access to specialist multidisciplinary management is limited. Academic tertiary referral centers offer cutting-edge diagnosis and treatment; however, in many parts of the region, patients are managed by non-specialists with limited resources. Due to many factors including lack of awareness and lack of prostate-specific antigen (PSA) screening, a high percentage of men present with locally advanced and metastatic prostate cancer at diagnosis. The aim of these recommendations is to assist clinicians in managing patients with different levels of access to diagnostic and treatment modalities. The first Advanced Prostate Cancer Consensus Conference (APCCC) satellite meeting for the Middle East was held in Beirut, Lebanon, November 2017. During this meeting a consortium of urologists, medical oncologists, radiation oncologist and imaging specialists practicing in Lebanon, Syria, Iraq, Kuwait and Saudi Arabia voted on a selection of consensus questions. An additional workshop to formulate resource-stratified consensus recommendations was held in March 2019. Variations in practice based on available resources have been proposed to form resource-stratified recommendations for imaging at diagnosis, initial management of localized prostate cancer requiring therapy, treatment of castration-sensitive/naïve advanced prostate cancer and treatment of castration-resistant prostate cancer. This is the first regional consensus on prostate cancer management from the Middle East. The following recommendations will be useful to urologists and oncologists practicing in all areas with limited access to specialist multi-disciplinary teams, diagnostic modalities and treatment resources.
Identifiants
pubmed: 31297628
doi: 10.1007/s00345-019-02872-x
pii: 10.1007/s00345-019-02872-x
pmc: PMC7064460
doi:
Substances chimiques
Androgen Antagonists
0
Antineoplastic Agents
0
Antineoplastic Agents, Hormonal
0
Benzamides
0
Nitriles
0
Docetaxel
15H5577CQD
Phenylthiohydantoin
2010-15-3
enzalutamide
93T0T9GKNU
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Abiraterone Acetate
EM5OCB9YJ6
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-693Références
J Glob Oncol. 2018 Jul;4:1-8
pubmed: 30110223
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
J Clin Oncol. 2018 May 10;36(14):1389-1395
pubmed: 29590007
Einstein (Sao Paulo). 2019 Mar 07;17(2):eGS4414
pubmed: 30843996
Clin Prostate Cancer. 2002 Dec;1(3):145-52
pubmed: 15046689
Lancet Oncol. 2016 Jun;17(6):747-756
pubmed: 27160475
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
N Engl J Med. 2017 Feb 2;376(5):417-428
pubmed: 28146658
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Pract Radiat Oncol. 2018 Nov - Dec;8(6):354-360
pubmed: 30322661
Eur Urol. 2014 Dec;66(6):1116-24
pubmed: 25052213
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Prostate. 2014 Feb;74(2):210-6
pubmed: 24132735
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
Cancer. 2016 Jul 1;122(13):2004-11
pubmed: 27028170
Eur Urol. 2016 Jun;69(6):1142-8
pubmed: 26749093
Eur Urol. 2018 Mar;73(3):436-444
pubmed: 28779974
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
J Clin Oncol. 2007 May 20;25(15):2035-41
pubmed: 17513807
Contemp Clin Trials. 2015 May;42:26-40
pubmed: 25749312
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Osteoporos Int. 2017 Jan;28(1):127-137
pubmed: 27650643
Ann Oncol. 2018 May 1;29(5):1235-1248
pubmed: 29529169
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
J Clin Oncol. 2019 May 10;37(14):1159-1168
pubmed: 30860948
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Eur Urol. 2018 Oct;74(4):432-441
pubmed: 29980331
J Urol. 2017 Mar;197(3 Pt 1):662-668
pubmed: 27614333
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
pubmed: 15173273
Cancer Med. 2016 Jan;5(1):136-41
pubmed: 26628287
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Radiat Oncol. 2017 Sep 7;12(1):149
pubmed: 28882187
Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48
pubmed: 24289901
N Engl J Med. 2018 Jun 28;378(26):2542
pubmed: 29949495